BrightEdge Ventures

BrightEdge is the American Cancer Society's philanthropic impact fund and venture capital arm, investing in for-profit oncology startups. It supports early-stage companies developing patient-centric solutions across the cancer care continuum. Leveraging its parent organization's expertise, the fund accelerates innovation and directly advances the American Cancer Society's mission.

Established by the American Cancer Society in 2019, BrightEdge was created to catalyze market activity in cancer innovation. This initiative arose from the insight that dedicated investment could address unmet needs while generating sustainable income for philanthropic efforts. Leveraging ACS's history as a cancer research funder, the fund translates scientific discovery into tangible solutions.

BrightEdge invests in oncology startups, providing capital and strategic support to companies aligning with the fight against cancer. Its portfolio companies pursue diverse therapies, diagnostics, and supportive care, improving patient outcomes. The fund seeks a double-bottom-line impact, integrating financial returns and mission-driven progress, ultimately enhancing the lives of cancer patients.